Category: Federal Forum Posters
Purpose: There is very limited data available on the use of DOACs in extremes of body weights. The International Society of Thrombosis and Haemostasis (2016) suggests avoiding use of direct oral anticoagulants in patients with a body mass index of greater than 40 kg/m2 or weight greater than 120kg. The Veterans Affairs Pharmacy Benefits Management Services recommends that when a direct oral anticoagulant is being considered in such patients, a shared decision-making approach should be utilized. The objective of this study is to determine the safety and efficacy of direct oral anticoagulants in obese patients compared to non-obese patients.
Methods: The study will be submitted to local Pharmacy & Therapeutics committee and Chief of Staff for approval and ethical consideration. The electronic medical record system will be utilized to identify patients currently receiving a direct oral anticoagulant from the Beckley Veterans Affair Medical Center. A retrospective chart review of those patients will be completed, in which the following data will be collected: patient age, patient weight, target medication name, dose, indication, renal function, hemoglobin, potential drug interactions, and occurrence of stroke or Venous Thromboembolism (VTE) since initiation of the direct oral anticoagulant. All data will be recorded without patient identifiers and maintained confidentially. Incidence of stroke and systemic embolic events will be compared between the obese and non-obese groups.
Results: not applicable
Conclusion: not applicable
Emily Keith– Pharmacy Resident, Beckley Veterans Affairs Medical Center, Fairdale, WV